In The News
Clyde & Co sued by insurers over indemnity advice
Cornwalls hits back at $4.8M negligence suit by former client
Top silk to join NSW Supreme Court
Ex-Bulldogs player must produce messages between solicitor and doctor
Child removal class actions launched against NSW, WA
NAB accused in suit of rescinding job offer to pregnant employee
Slater & Gordon denies firing HR head for reporting underpayments
Wealth guru Dominique Grubisa pleads ignorance in appeal of $6M penalty
Court finds former Orix boss engaged in fraud, throws out suit against Chubb
Cruise operators face potential class action over onboard gambling
Please login to bookmarkClose

Novartis has applied to amend its proposed patent for an oral form of multiple sclerosis drug Gilenya, as it appeals an invalidity ruling by IP Australia for lack of inventive step.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?
error: The content is secured.

For information on rights and reprints, contact subscriptions@lawyerly.com.au